NuVasive, Inc. (NASDAQ:NUVA) Files An 8-K Submission of Matters to a Vote of Security Holders

NuVasive, Inc. (NASDAQ:NUVA) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07Submission of Matters to a Vote of Security Holders.

On May 18, 2017, NuVasive, Inc. (the Company) held its Annual
Meeting of Stockholders (the Annual Meeting). The Companys
definitive proxy statement for the Annual Meeting was filed with
the U.S. Securities and Exchange Commission (the SEC) on April 5,
2017 and describes in detail each of the four proposed voting
matters (the Proposals) submitted to the Companys stockholders at
the Annual Meeting. The final results for the votes cast with
respect to each Proposal are set forth below.

As of March 23, 2017, the record date of the Annual Meeting,
there were 50,660,272 outstanding shares of the Companys common
stock. At the Annual Meeting, a quorum of 47,871,429 shares of
the Companys common stock were represented in person or by proxy.

Proposal 1

The stockholders elected each of Gregory T. Lucier, Leslie V.
Norwalk and Michael D. OHalleran as a Class I director to hold
office until the 2020 Annual Meeting of Stockholders, and in each
case until their respective successors are duly elected and
qualified, by the following vote:

Proposal 2

The stockholders ratified the appointment of Ernst Young LLP as
the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017 by the following vote:

Proposal 3

The stockholders approved, on a non-binding advisory basis, the
compensation of the Companys named executed officers for the
fiscal year ended December 31, 2016, as disclosed in the Companys
proxy statement for the Annual Meeting to the compensation
disclosure rules of the SEC, by the following vote:

Proposal 4

The stockholders approved holding the non-binding advisory vote
on the compensation of the Companys named executive officers on
an annual basis. The number of votes cast for 1 year, 2 years, 3
years, and the number of abstentions and broker non-votes were as
follows:

No other items were presented for stockholder approval at the
Annual Meeting.

In light of the results of the stockholder vote on the frequency
of future non-binding advisory votes on the compensation of the
Companys named executive officers, and consistent with the
Companys recommendation, the Companys Board of Directors has
determined that the Company will hold a non-binding advisory vote
on executive compensation annually until the next required vote
on the frequency of future non-binding advisory votes on the
compensation of the Companys named executive officers.

About NuVasive, Inc. (NASDAQ:NUVA)
Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process. NuVasive, Inc. (NASDAQ:NUVA) Recent Trading Information
NuVasive, Inc. (NASDAQ:NUVA) closed its last trading session down -0.81 at 70.44 with 717,327 shares trading hands.